MedTrace Logo

COVID-19 Vaccination Status and The Clinical Outcomes of Long COVID-19 Patients

NCT05587868 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 250

Last updated 2022-10-28

No results posted yet for this study

Summary

Long COVID is defined by the persistence or emergence of symptoms for more than 4 weeks beyond the acute phase of Severe Acute Respiratory Syndrome-Corona Virus-2 (SARS-CoV-2) infection. As the number of cases increases and various strains of SARS-CoV-2 emerge, so does the number of long COVID cases. Various multi-organ complications after COVID-19 infection include respiratory, cardiovascular, gastrointestinal, hepatobiliary, metabolic, and neuropsychiatric disorders. The symptoms and characteristics of Long COVID vary in each country.

Vaccination against SARS-CoV-2 has been documented to increase clinical resolution of Long COVID. In Indonesia, current full-dose vaccination coverage had merely reached 15.6% of the national vaccination target. This condition can be predictably associated with a longer duration and higher severity of symptoms in Long COVID patients.

The purpose of this study is to provide an overview of the symptoms and characteristics and determine whether vaccination against SARS-CoV-2 could improve clinical outcomes and quality of life of Long COVID patients at Dr. Cipto Mangunkusumo General Hospital.

Conditions

Interventions

BIOLOGICAL

COVID-19 Vaccine

Mandatory COVID-19 vaccination as part of the the Indonesian national government program.

Sponsors & Collaborators

  • Indonesia University

    lead OTHER

Principal Investigators

  • Eric D Tenda, MD, DIC, PhD · Fakultas Kedokteran Universitas Indonesia - Dr Cipto Mangunkusumo General Hospital

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-03-11
Primary Completion
2022-11-30
Completion
2023-05-31

Countries

  • Indonesia

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05587868 on ClinicalTrials.gov